Seroepidemiology of human T-cell lymphotropic virus type-I in blood donors of Northeastern Iran, Sabzevar

Asian Journal of Transfusion Science

Volumn 9, Issue 2, 2015, Pages 203-206

  Maghsudlu, Mahtab ^a   Safabakhsh, Hamidreza ^a,b   Jamili, Parastoo ^a,c  

^a HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

^b Mashhad Regional Educational Blood Transfusion Center   (Iran)

^c Sabzevar Blood Transfusion Center   (Iran)

Author keywords

Blood donors; Human T cell lymphotropic virus type I; Iran; Sabzevar; Seroprevalence

Indexed keywords

EID: 84939789503     PISSN: 09736247     EISSN: 19983565     Source Type: Journal    
DOI: 10.4103/0973-6247.154255     Document Type: Article

References (30)

1. Verdonc k K, González E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: Recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7: 266-81.
2. Bitt encourt AL, Primo J, Oliveira MF. Manifestations of the human T-cell lymphotropic virus type I infection in childhood and adolescence. J Pediatr (Rio J) 2006; 82: 411-20.
3. Edlich RF, Hill LG, Williams FM. Global epidemic of human T-cell lymphotrophic virus type-I (HTLV-I): An update. J Long Term Eff Med Implants 2003; 13: 127-40.
4. Azarpazhooh MR, Hasanpour K, Ghanbari M, Rezaee SA, Mashkani B, Hedayati-Moghaddam MR, et al. Human T-lymphotropic virus type 1 prevalence in northeastern Iran, Sabzevar: An epidemiologic-based study and phylogenetic analysis. AIDS Res Hum Retroviruses 2012; 28: 1095-101.
5. Jamili P, Safabakhsh H, Marvi M, Shakeri M, Bazargani R. Seroepidemiology of HTLV-I infection in Sabzevar blood donors from 2007 to 2008. J Sabzevar Univ Med Sci 2014; 20: 464-71.
6. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: A population-based seroepidemiology survey. J Clin Virol 2011; 52: 172-6.
7. Safabakhsh H, Jalalian M, Karimi G. The prevalence of HTLV-1 infection in blood donation volunteers in Mashhad. Glob J Health Sci 2014; 6: 99-104.
8. Karimi A, Nafici MR, Imani K. Comparison of human T-cell leukemia virus type 1 seroprevalence in high risk patients (thalassemia and hemodialysis) and healthy individuals from Charmahal-Bakhtiari province, Iran. Kuwait Med J 2007; 39: 259-61.
9. Khameneh ZR, Baradaran M, Sepehrvand N. Survey of the seroprovalence of HTLV I/II in hemodialysis patients and blood donors in Urmia. Saudi J Kidney Dis Transpl 2008; 19: 838-41.
10. Falahi S, Sabahi F, Zeynali M, Kiani J, Ranjbar J. Incidence of human T-lymphotropic virus type-1 (HTLV1) among blood donors from Ilam, Iran. Iran J Virol 2008; 1: 11-4.
11. Abedi F, Yavarian M, Shakibzadeh A, Khalvati B, Asadi AH. A pilot Seroepidemiologic study of HTLV in thalassemia, hemophilia, and hemodialysed patients in Hormozgan. Med J Hormozgan Univ 2009; 13: 75-80.
12. Karim MR, Pour GH, Zandi K, Roustaei MH. Prevalence of anti-HTLV-I & anti-HTLV-II antibodies in blood donors in Bushehr province. Iran S Med J 2004; 2: 164-1.
13. Rafatpanah H, Farid R, Golanbar G, Jabbari Azad F. HTLV-I infection: Virus structure, immune response to the virus and genetic association studies in HTLV-I-infected individuals. Iran J Allergy Asthma Immunol 2006; 5: 153-66.
14. Ghafouri M, Ameli MR. Transfusion transmitt ed viral infections in blood donors of South Khorasan. Sci J Iran Blood Transfus Organ 2011; 7: 242-8.
15. Chaudhari SC, Shah T, Misra SC. Prevalence of human T cell leukaemia virus amongst blood donors. Med J Armed Forces India 2009; 65: 38-40.
16. Senyuta N, Syrtsev A, Yamashita M, Stepina V, Susova O, Scherbak L, et al. Sero-epidemiologic and phylogenetic studies of HTLV-I infection in 2 countries of the Caspian Sea region. Int J Cancer 1998; 77: 488-93.
17. Sertöz R, Turhan A, Bozkurt H, Samlioglu P, Degirmenci A, Aydinok Y, et al. Investigation of anti-HTLV I/II seroprevalence in healthy blood donors in Izmir region, Turkey. Mikrobiyol Bul 2010; 44: 579-84.
18. Ul-Hassan Z, Al-Bahrani AT, Panhotra BR. Prevalence of human T-lymphotropic virus type I and type II antibody among blood donors in Eastern Saudi Arabia. Saudi Med J 2004; 25: 1419-22.
19. Al-Mutti S, Voevodin A, Ahmed S, Al Hamdan S, Al-Basheer AA. Seroprevalence of human T-cell leukemia/lymphoma virus type I and type II (HTLV-I/HTLV-II) infection among volunteer blood donors in Kuwait. Med Princ Pract 1999; 8: 45-50.
20. Carneiro-Proietti AB, Sabino EC, Leão S, Loureiro P, Sarr M. HTLV-1/2 prevalence in Brazilian blood donors: Regional and demographic variation. Retrovirology 2011; 8 Suppl 1: A83.
21. Diop S, Calattini S, Abah-Dakou J, Thiam D, Diakhaté L, Gessain A. Seroprevalence and molecular epidemiology of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 in blood donors from Dakar, Senegal. J Clin Microbiol 2006; 44: 1550-4.
22. Tamim H, Musharrafieh U, Ramia S, Almawi WY, Al-Jisr T, Ayoub T, et al. Is seroprevalence of HTLV-I/II among blood donors in Lebanon relevant? Am J Infect Control 2004; 32: 220-3.
23. Kwon SY, Lim AH, Park JY, Han SH, Cho NS. Seroprevalence of human T-lymphotropic virus type 1 and 2 in Korean blood donors. J Med Virol 2008; 80: 1864-7.
24. Lu SC, Kao CL, Chin LT, Chen JW, Yang CM, Chang JH, et al. Seroprevalence and demographic characteristics of HTLV-I among blood donors in Taiwan: 1996-1999. Int J Hematol 2001; 74: 333-7.
25. Couroucé AM, Pillonel J, Lemaire JM, Maniez M, Brunet JB. Seroepidemiology of HTLV-I/II in universal screening of blood donations in France. AIDS 1993; 7: 841-7.
26. Stigum H, Magnus P, Samdal HH, Nord E. Human T-cell lymphotropic virus testing of blood donors in Norway: A cost-effect model. Int J Epidemiol 2000; 29: 1076-84.
27. Toro C, Rodés B, Aguilera A, Caballero E, Benito R, Tuset C, et al. Clinical impact of HTLV-1 infection in Spain: Implications for public health and mandatory screening. J Acquir Immune Defi c Syndr 2002; 30: 366-8.
28. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005; 24: 6058-68.
29. Abolghasemi H, Maghsudlu M, Amini Kafi-Abad S, Cheraghali A. Introduction to Iranian Blood Transfusion Organization and blood safety in Iran. Iran J Public Health 2009; 38 Suppl 1: 82-7.
30. Maghsudlu M, Nasizadeh S. Iranian blood donors' motivations and their infl uencing factors. Transfus Med 2011; 21: 247-52.